ES2785094T3 - Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados - Google Patents

Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados Download PDF

Info

Publication number
ES2785094T3
ES2785094T3 ES12850971T ES12850971T ES2785094T3 ES 2785094 T3 ES2785094 T3 ES 2785094T3 ES 12850971 T ES12850971 T ES 12850971T ES 12850971 T ES12850971 T ES 12850971T ES 2785094 T3 ES2785094 T3 ES 2785094T3
Authority
ES
Spain
Prior art keywords
glutamine
salt
diabetes
use according
person
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12850971T
Other languages
English (en)
Spanish (es)
Inventor
Yutaka Niihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emmaus Medical Inc
Original Assignee
Emmaus Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48470183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2785094(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emmaus Medical Inc filed Critical Emmaus Medical Inc
Application granted granted Critical
Publication of ES2785094T3 publication Critical patent/ES2785094T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ES12850971T 2011-11-21 2012-11-17 Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados Active ES2785094T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161629633P 2011-11-21 2011-11-21
PCT/US2012/000557 WO2013077893A1 (en) 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms

Publications (1)

Publication Number Publication Date
ES2785094T3 true ES2785094T3 (es) 2020-10-05

Family

ID=48470183

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12850971T Active ES2785094T3 (es) 2011-11-21 2012-11-17 Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados

Country Status (10)

Country Link
US (2) US20130143968A1 (cg-RX-API-DMAC7.html)
EP (2) EP2782588B1 (cg-RX-API-DMAC7.html)
JP (4) JP6089042B2 (cg-RX-API-DMAC7.html)
CN (3) CN108354916A (cg-RX-API-DMAC7.html)
BR (1) BR112014011898A2 (cg-RX-API-DMAC7.html)
ES (1) ES2785094T3 (cg-RX-API-DMAC7.html)
HK (1) HK1257401A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014KN01037A (cg-RX-API-DMAC7.html)
PH (2) PH12014501052B1 (cg-RX-API-DMAC7.html)
WO (1) WO2013077893A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
WO2003072556A1 (en) * 2001-06-27 2003-09-04 Prosidion Ltd. Glutaminyl based dpiv inhibitors
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
TWI351278B (en) * 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
CN101472579B (zh) * 2006-04-22 2013-07-03 霍利斯-伊登医药公司 药物和用途
EP2077110A4 (en) * 2006-09-29 2012-06-27 Ajinomoto Kk GLUTAMINE-CONTAINING COMPOSITION FOR INCREASING BLOOD FLOW
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
KR20110120866A (ko) * 2009-01-12 2011-11-04 바이오키어 인코포레이티드 당뇨병 치료 조성물 및 치료방법
NL1036746C2 (nl) * 2009-03-20 2010-09-21 Glnp Holding B.V. Kit van onderdelen bevattende l-glutamine en egcg.
BR112012006437A2 (pt) * 2009-09-23 2016-04-19 Biokier Inc composições e métodos para tratamento do diabetes e outros distúrbios

Also Published As

Publication number Publication date
IN2014KN01037A (en) 2015-10-09
CN103945858A (zh) 2014-07-23
WO2013077893A1 (en) 2013-05-30
CN108354916A (zh) 2018-08-03
HK1257401A1 (zh) 2019-10-18
JP6389495B2 (ja) 2018-09-12
EP2782588B1 (en) 2020-04-15
JP2014533689A (ja) 2014-12-15
JP2017052766A (ja) 2017-03-16
PH12014501052A1 (en) 2014-06-30
US20190192463A1 (en) 2019-06-27
BR112014011898A2 (pt) 2017-05-16
PH12020550726B1 (en) 2022-11-09
EP2782588A1 (en) 2014-10-01
EP3437649A1 (en) 2019-02-06
JP2018115175A (ja) 2018-07-26
PH12020550726A1 (en) 2021-06-14
JP2018199692A (ja) 2018-12-20
CN108478551A (zh) 2018-09-04
PH12014501052B1 (en) 2020-10-09
EP2782588A4 (en) 2015-05-20
US20130143968A1 (en) 2013-06-06
JP6089042B2 (ja) 2017-03-01
JP6550160B2 (ja) 2019-07-24

Similar Documents

Publication Publication Date Title
US11141399B2 (en) Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
ES2820025T3 (es) Uso de derivados 2-hidroxilados de ácidos grasos poliinsaturados como medicamentos
US11224585B2 (en) Compositions containing omega-3 oil and uses thereof
JP7514457B2 (ja) 片頭痛の予防および治療
CN103285394B (zh) 使用硝化脂质治疗脂质病症和肥胖以及与脂质和肥胖相关的病状
US20190183839A1 (en) Methods of treating pediatric metabolic syndrome
EP2468273A2 (en) Method to reduce oxidative damage and improve mitochondrial efficiency
ES2785094T3 (es) Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados
JP2017519028A (ja) 重度の高トリグリセリド血症の処置
US20240382445A1 (en) Methods of adjuvant therapy
CN110139645A (zh) 用于预防和/或治疗恶病质的ω-3脂肪酸组合物
CN121176626A (zh) 用于调控神经递质的膳食补充剂及其制备方法和应用
ES2379165T3 (es) Uso de un agonista de PPAR-alfa para tratar la ganancia de peso asociada con un tratamiento con un agonista de PPAR-Gamma
CN117653642A (zh) 格列本脲促进nad+水平的用途
CA3234879A1 (en) Medium chain dicarboxylic acids for the treatment and prevention of diseases and conditions
HK1216847A1 (zh) 用於产生升高和持久的酮症的组合物和方法